Vertex Pharmaceuticals Incorporated and Parion Sciences recently announced a joint collaboration for the development of investigational epithelial sodium channel (ENaC) inhibitors to treat cystic fibrosis (CF) and other pulmonary conditions. Based on the agreement rights, Vertex will develop and commercialize Parion’s ENaC inhibitors, named P-1037 and P-1055, for…
cystic fibrosis
The U.K. based Cystic Fibrosis Trust, a national charity that funds research into the disease and provides information and support for patients and families, has announced that the nonprofit organization will standardize using DocuSign for Digital Transaction Management in order to eliminate printing, faxing, scanning and overnighting documents in…
Celtaxsys has announced that the company’s phase 2 clinical trial to evaluate CTX-4430, its investigational treatment for cystic fibrosis (CF), will be supported by a $5 million grant from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The CFFT is the non-profit drug discovery and development affiliate of the Cystic Fibrosis…
The Best Late Stage Product Development Company Award was recently granted to Parion Sciences by the Triangle Business Journal and accounting firm BDO. The company, which is focused on creating novel therapies for both pulmonary and ocular medical conditions, was presented with the award at an event in Cary, North Carolina, and is part of the third-annual…
Denmark-based Serendex Pharmaceuticals, a company developing drugs to treat severe respiratory conditions, recently announced the initiation of a Phase I clinical trial for their drug candidate Molgradex, based on their Granulocyte Macrophage Colony Stimulating Factor (GM-CSF). The compound uses Novozymes‘ recombinant human albumin named Recombumin as an effective, versatile stabilizer that eases…
La Jolla Pharmaceutical Acquires Rights To Gentamicin Derivatives For Cystic Fibrosis Treatment
In a recent agreement with the Indiana University Research and Technology Corp. (IURTC), La Jolla Pharmaceutical Co. acquired intellectual property rights covering next-generation derivatives of gentamicin, an antibiotic used in the treatment of several types of bacterial infections, namely heart, urinary tract, and pregnancy-related infections. Gentamicin treatment is effective…
Despite every effort to design a drug effective in helping cystic fibrosis patients with defective CFTR proteins, sometimes drugs are thwarted by mechanisms orchestrated by other proteins within cells. A group of researchers from the Department of Human Genetics at National Health Institute Doutor Ricardo Jorge in Portugal recently published…
Researchers at the University of Missouri–Columbia have discovered two key amino acids in the protein that is associated with cystic fibrosis (CF) — cystic fibrosis transmembrane conductance regulator (CFTR) protein. The study is entitled “Localizing a gate in CFTR” and was published in the journal…
New Research Into Bacterial Behavior Could Aid in Mitigating Antibiotic Resistance in CF Patients
Researchers from The University of Texas at Austin recently revealed that the pathogenic bacteria Pseudomonas aeruginosa has the capacity to inhibit its own growth and the growth of antibiotic-resistant mutants. The study entitled “The spatial profiles and metabolic capabilities of microbial…
Caleigh Haber is an artist, blogger and the focus of this month’s Happiness Stories video series. To celebrate Cystic Fibrosis Awareness Month, the series is sharing the story of Caleigh, who despite living with cystic fibrosis (CF), tries to always see…
Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Recent Posts
- Having friends in the CF community makes all the difference to me January 16, 2026
- A trial that fails to reach its clinical endpoints isn’t necessarily a ‘failure’ January 15, 2026
- CF treatment Alyftrek tops Trikafta for boosting life quality: Analysis January 15, 2026
- Antibody therapy to clear CF lung infections fares well in early trial January 13, 2026
- KB407 gene therapy shows promise for all CFTR mutations in CF January 12, 2026